May 16, 2024
Headlines

CNS

Cohen & Steers, Inc. (CNS) Q1 2024 Earnings Call Transcript

admin058 mins

Cohen & Steers, Inc. (NYSE:CNS) Q1 2024 Earnings Conference Call April 18, 2024 10:00 AM ET Company Participants Brian Heller – SVP & Corporate CounselMatthew Stadler – CFOJoseph Harvey – CEO & PresidentJon Cheigh – Chief Investment Officer Conference Call Participants John Dunn – Evercore ISIAdam Beatty – UBS Operator Ladies and gentlemen, thank you…

Read More

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position (COYA)

admin013 mins

BlackJack3D Coya Therapeutics (NASDAQ:COYA) targets inflammation by modulating the function of regulatory T cells (Tregs) in neurological diseases. The “original” lead asset used to be COYA 101, an autologous regulatory T-cell product candidate with a completed Phase 2a trial in Amyotrophic Lateral Sclerosis under its belt. The trial was completed way back in 2022. However,…

Read More